Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02509507




Registration number
NCT02509507
Ethics application status
Date submitted
10/07/2015
Date registered
28/07/2015
Date last updated
25/07/2023

Titles & IDs
Public title
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
Scientific title
A Phase 1b/2, Multicenter, Open-label, Basket Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab in Phase 1b and to Evaluate the Efficacy and Safety of Intratumoral Talimogene Laherparepvec in Combination With Systemic Pembrolizumab to Treat Subjects With Advanced Solid Tumors in Phase 2 (MASTERKEY-318)
Secondary ID [1] 0 0
2014-005386-67
Secondary ID [2] 0 0
20140318
Universal Trial Number (UTN)
Trial acronym
MASTERKEY-318
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hepatocellular Carcinoma 0 0
Liver Metastases 0 0
Cutaneous or Subcutaneous Lymph Node 0 0
Liver Tumors 0 0
Condition category
Condition code
Cancer 0 0 0 0
Liver
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Talimogene Laherparepvec
Treatment: Drugs - Pembrolizumab

Experimental: Phase Ib/II Talimogene Laherparepvec - Talimogene Laherparepvec

Experimental: Phase Ib/II Talimogene Laherparepvec + Pembrolizumab - Combination treatment of Talimogene Laherparepvec and Pembrolizumab


Treatment: Drugs: Talimogene Laherparepvec
Talimogene laherparepvec (T-VEC) administered by intralesional injection into liver tumors, with ultrasound/computed tomography (US/CT) guidance. Part 1: initial dose of T-VEC is 10^6 plaque forming unit (PFU)/mL up to 4mL in Cohorts 1 & 2, up to 8mL in Cohorts 3 & 4 of the Group A & Group B. The 1st cycle of T-VEC will be 21 (+3) days (from the 1st dose at 10^6 PFU/mL to the 2nd dose at 10^7 or 10^8 PFU/mL). Subsequent cycles of T-VEC will be 21 (±3) days. Max. volume of T-VEC administered at any dose is 4mL (Cohorts 1, 2, 5, and 6) or 8mL (Cohorts 3 & 4) for any individual lesion or for all lesions combined. Part 2: Initial dose of T-VEC is 10^6 PFU/mL followed by subsequent T-VEC doses at a concentration of 10^8 PFU/mL. T-VEC volume is up to 8mL based on the size of the inejected lesions. NOTE: as of Protocol Amendment 6 [dated 26 October 2021], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer performed in this study.

Treatment: Drugs: Pembrolizumab
Pembrolizumab is a non-Amgen Investigational product that is manufactured by Merck. Pembrolizumab will be labeled, packaged, and distributed by Amgen (or designee) using Amgen (or designee) clinical study drug distribution procedures. Pembrolizumab is supplied as pembrolizumab 100 mg/4 mL vials (25 mg/mL) solution for IV infusion. The trial treatment will consist of a total dose of 200mg administered intravenously every 3 weeks (day 1 of each cycle) for up to 35 cycles.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)
Timepoint [1] 0 0
Cycle 1 and Cycle 2: Day 1 to Day 21
Primary outcome [2] 0 0
Part 2 Only: Objective Response Rate (ORR)
Timepoint [2] 0 0
Week 10, then every 9 weeks thereafter. The maximum duration of talimogene laherparepvec treatment at data cut off was 61.0 weeks and pembrolizumab treatment at data cut off was 98.3 weeks.
Primary outcome [3] 0 0
Part 2 Only: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
Timepoint [3] 0 0
Day 1 to 30 days post-last dose of talimogene laherparepvec. The maximum duration of talimogene laherparepvec treatment at data cut off was 61.0 weeks and pembrolizumab treatment at data cut off was 98.3 weeks.

Eligibility
Key inclusion criteria
Summary of Subject Eligibility Criteria:

Key

Subjects must be age = 18 years at the time of informed consent. Subjects must have
histologically or cytologically confirmed disease.

Part 1 is restricted to BC, CRC, GEC, melanoma, NSCLC, or RCC with liver metastases or HCC.

Part 2 Group A is restricted to advanced hormone receptor positive BC, CRC, TNBC, CSCC, and
BCC with or without liver metastases.

- Part 2 Hormone receptor positive Breast Cancer Arm only: Histologically and/or
cytologically confirmed diagnosis of estrogen receptor (ER) positive and/or
progesterone receptor (PrR) positive breast cancer.

- Triple negative breast cancer: Histologically and/or cytologically confirmed diagnosis
of ER negative, PrR negative, human epidermal growth factor receptor 2 (HER2)-Neu
negative.

Part 2 Group B is restricted to HCC (fibrolamellar and mixed
hepatocellular/cholangiocarcinoma subtypes are not eligible).

For HCC subjects with a diagnosis of hepatitis B, they must be on antiviral therapy for at
least 4 weeks prior to enrollment and hepatitis B virus (HBV) viral load by real-time
polymerase chain reaction (qPCR) must be < 100 IU/mL. HCC subjects with past or ongoing
hepatitis C infection must have completed treatment for hepatitis C at least 1 month prior
to study enrollment and hepatitis C viral load must be undetectable; subjects with
hepatitis B and C must fulfill the eligibility criteria for hepatitis B and hepatitis C.
Subjects with unresectable locally recurrent TNBC are eligible.

Non-HCC subjects must have received at least 1 prior standard of care systemic anti-cancer
therapy for their locally advanced or metastatic disease. For the combination cohorts
(Cohorts 5 and 6 in Part 1) and Part 2, subjects with melanoma CSCC or NSCLC do not need to
have received prior therapy. In Part 1, subjects must have measurable liver tumors and
liver tumors that are suitable for injection. In Part 2, subjects must have measurable
disease and cutaneous, subcutaneous, lymph node, or liver tumors suitable for injection.
NOTE: as of Protocol Amendment 6 [dated 26 October 2021], intrahepatic injections of
talimogene laherparepvec and liver biopsies are no longer performed in this study,
enrollment for this study has stopped. Eastern Cooperative Oncology Group (ECOG)
performance status must be 0 or 1, and life expectancy should be approximately 5 months or
more. Adequate hematological, renal, hepatic, and coagulation function is required. Liver
function tests may be mildly abnormal but within the parameters. Child-Pugh score must be
A.

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Subjects must not be candidates for surgery or locoregional therapy with curative intent or
planned systemic anti-cancer therapy, with the exception of immunotherapy in the
combination cohorts (Cohorts 5 and 6 in Part 1 and all subjects in Part 2). Liver tumors
must not be estimated to invade approximately more than one-third of the liver. Liver
tumor-directed therapy, hepatic surgery or major surgery, antibody-based therapy, or
immunotherapy must not have been performed < 28 days, chemotherapy < 21 days, and targeted
small molecule therapy or hormonal therapy < 14 days prior to enrollment. Subjects must
either (1) have no central nervous system (CNS) metastasis, or carcinomatous meningitis, or
(2) if CNS metastasis is present, must have stable treated cerebral metastases. Subjects
must not have symptomatic auto-immune disease or be symptomatically immunosuppressed. They
must not have a history of solid organ transplantation. For non-HCC, there must not be
acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. For HCC with
prior hepatitis B and/or C infection, HBV and/or HCV viral load by qPCR must be
undetectable, and they must not have had recent treatment within 12 weeks for HBV or HCV
with certain antiviral medications in Part 1 Group B cohorts 1-5 and 6a, and Part 2 Group B
HCC without viral hepatitis. For all patients in Part 1 and for patients in Part 2 where
intrahepatic liver injection is planned (NOTE: as of Protocol Amendment 6 [dated 26 October
2021], intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer
performed in this study, enrollment for this study has stopped), there should be no
macroscopic intravascular invasion of tumors into the main portal vein, hepatic vein, or
vena cava. Subjects must not: have active herpetic skin lesions or prior complications of
herpetic infection (eg, herpetic keratitis or encephalitis); require treatment with an
antiherpetic drug; have received live-virus vaccination within 30 days of planned treatment
start; have previous therapy with talimogene laherparepvec, oncolytic viruses, or tumor
vaccine. Subjects in the combination treatment cohort must not have: a history or evidence
of psychiatric, substance abuse, or any other clinically significant disorder; toxic
effects of the most recent prior chemotherapy not resolved to grade 1 or less (except
alopecia); or expected other cancer therapy while on study with the exception of local
radiation to the site of bone or other metastasis for palliative treatment. Male subjects
of reproductive potential in the combination treatment must be willing to use acceptable
methods of effective contraception during treatment and through 4 months after the last
dose of pembrolizumab.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
5/02/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/07/2023
Sample size
Target
Accrual to date
Final
127
Recruitment in Australia
Recruitment state(s)
NSW,QLD
Recruitment hospital [1] 0 0
Liverpool Hospital - Liverpool
Recruitment hospital [2] 0 0
Melanoma Institute Australia - North Sydney
Recruitment hospital [3] 0 0
Tasman Oncology Research - Southport
Recruitment postcode(s) [1] 0 0
2170 - Liverpool
Recruitment postcode(s) [2] 0 0
2060 - North Sydney
Recruitment postcode(s) [3] 0 0
4215 - Southport
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Kentucky
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
New Jersey
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
Pennsylvania
Country [9] 0 0
United States of America
State/province [9] 0 0
Texas
Country [10] 0 0
Austria
State/province [10] 0 0
Salzburg
Country [11] 0 0
Belgium
State/province [11] 0 0
Bruxelles
Country [12] 0 0
Belgium
State/province [12] 0 0
Edegem
Country [13] 0 0
Belgium
State/province [13] 0 0
Gent
Country [14] 0 0
Germany
State/province [14] 0 0
Berlin
Country [15] 0 0
Germany
State/province [15] 0 0
Bonn
Country [16] 0 0
Germany
State/province [16] 0 0
Reutlingen
Country [17] 0 0
Germany
State/province [17] 0 0
Tübingen
Country [18] 0 0
Korea, Republic of
State/province [18] 0 0
Seongnam-si, Gyeonggi-do
Country [19] 0 0
Korea, Republic of
State/province [19] 0 0
Seoul
Country [20] 0 0
Poland
State/province [20] 0 0
Gdansk
Country [21] 0 0
Spain
State/province [21] 0 0
Cataluña
Country [22] 0 0
Spain
State/province [22] 0 0
Madrid
Country [23] 0 0
Switzerland
State/province [23] 0 0
Geneva 14
Country [24] 0 0
Switzerland
State/province [24] 0 0
Lausanne
Country [25] 0 0
Switzerland
State/province [25] 0 0
Winterthur
Country [26] 0 0
Switzerland
State/province [26] 0 0
Zurich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Amgen
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This is a phase 1b/2, multicenter, open-label, basket trial to evaluate the safety of
talimogene laherparepvec injected intrahepatically into liver tumors alone and in combination
with systemic intravenous (IV) administration of pembrolizumab, in subjects with
non-hepatocellular carcinoma (HCC) liver metastases from breast adenocarcinoma (BC),
colorectal adenocarcinoma (CRC), gastroesophageal cancer (GEC), melanoma, non-small cell lung
cancer (NSCLC), clear cell renal cell carcinoma (RCC) in Part 1 Group A, and subjects with
HCC with and without viral hepatitis in Part 1 Group B (viral hepatitis is only applicable in
combination setting), and to evaluate the efficacy and safety of intratumoral talimogene
laherparepvec in combination with systemic pembrolizumab in subjects with advanced triple
negative breast cancer (TNBC), hormone receptor positive breast cancer, CRC, cutaneous
squamous cell carcinoma (CSCC), and basal cell carcinoma (BCC) in Part 2 Group A and subjects
with HCC with and without viral hepatitis in Part 2 Group B. The objective of Part 1 is to
evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors
alone and in combination with systemically administered pembrolizumab for the non-HCC (Group
A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the
efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab.
Efficacy and safety will be evaluated in each of the five non-HCC tumor types from Group A
separately. Similarly, the efficacy and safety of the combination treatment will be
determined for Group B HCC subjects. As of Protocol Amendment 6 (dated 26 October 2021),
intrahepatic injections of talimogene laherparepvec and liver biopsies are no longer
performed in this study. Enrollment for this study has stopped.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02509507
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02509507